US regulatory status: approved. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Cyclooxygenase inhibitor
pharma · Hypertension · Breast Neoplasms
Pfizer
Pfizer drug portfolio — 63 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
New York 10017, US HQ
103,316 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- New York 10017, US
- Employees
- 103,316
- Programs
- 0
- Drugs
- 63
- Patents
- 0
Pfizer pipeline
Portfolio lens on 63 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Pfizer drug portfolio — 63 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
amlodipine
Cardiovascular system (C09)Cardiovascular system (C09) compound in Pfizer's portfolio. Mechanism: Voltage-gated L-type calcium channel blocker.
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
Development asset linked to Pfizer in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Voltage-gated L-type calcium channel.
- Target
- Voltage-gated L-type calcium channel
- Mechanism
- Voltage-gated L-type calcium channel blocker
-
anidulafungin
Antiinfectives for systemic use (J02)US regulatory status: approved. Molecular target: 1,3-beta-glucan synthase.
- Target
- 1,3-beta-glucan synthase
- Mechanism
- 1,3-beta-glucan synthase inhibitor
-
apixaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
artesunate
Antiparasitic products (P01)US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Pfizer in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
- Target
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Mechanism
- HMG-CoA reductase inhibitor
-
avelumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 other
-
axitinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
binimetinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase 1 inhibitor
-
bosutinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Pfizer's portfolio. Molecular target: Tyrosine-protein kinase ABL1.
- Target
- Tyrosine-protein kinase ABL1
- Mechanism
- Tyrosine-protein kinase ABL inhibitor
-
brentuximab vedotin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved.
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
ceftaroline fosamil
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
ceftazidime
Antiinfectives for systemic use (J01)US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.
- Target
- Bacterial penicillin-binding protein
- Mechanism
- Bacterial penicillin-binding protein inhibitor
-
celecoxib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Pfizer's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
crizotinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ALK tyrosine kinase receptor.
- Target
- ALK tyrosine kinase receptor
- Mechanism
- Hepatocyte growth factor receptor inhibitor
-
dexmedetomidine
Nervous system (N05)Nervous system (N05) compound in Pfizer's portfolio. Mechanism: Adrenergic receptor alpha-2 agonist.
- Mechanism
- Adrenergic receptor alpha-2 agonist
-
Development asset linked to Pfizer in public FDA and regional records.
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
etanercept
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
US regulatory status: approved. Molecular target: Solute carrier family 12 member 3.
- Target
- Solute carrier family 12 member 3
- Mechanism
- Thiazide-sensitive sodium-chloride cotransporter inhibitor
-
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Pfizer's portfolio.
-
inotuzumab ozogamicin
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-cell receptor CD22.
- Target
- B-cell receptor CD22
- Mechanism
- CD22 binding agent
-
US regulatory status: approved. Molecular target: Cyclooxygenase.
- Target
- Cyclooxygenase
- Mechanism
- Cyclooxygenase inhibitor
-
maraviroc
Antiinfectives for systemic use (J05)US regulatory status: approved. Molecular target: C-C chemokine receptor type 5.
- Target
- C-C chemokine receptor type 5
- Mechanism
- C-C chemokine receptor type 5 antagonist
-
methotrexate
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Dihydrofolate reductase inhibitor
-
Development asset linked to Pfizer in public FDA and regional records.
-
Development asset linked to Pfizer in public FDA and regional records. Molecular target: Type-1 angiotensin II receptor.
- Target
- Type-1 angiotensin II receptor
- Mechanism
- Type-1 angiotensin II receptor antagonist
-
palbociclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: CDK6/cyclin D1.
- Target
- CDK6/cyclin D1
- Mechanism
- Cyclin-dependent kinase 4/cyclin D1 inhibitor
-
pegaptanib
Sensory organs (S01)Sensory organs (S01) compound in Pfizer's portfolio. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A antagonist
-
US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A antagonist
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
pregabalin
Nervous system (N02)US regulatory status: approved. Molecular target: Voltage-gated calcium channel.
- Target
- Voltage-gated calcium channel
- Mechanism
- Voltage-gated calcium channel modulator
-
quadrivalent influenza vaccine (recombinant, prepared in cell culture)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in Pfizer's portfolio.
-
rimegepant
Nervous system (N02)US regulatory status: approved. Molecular target: Calcitonin gene-related peptide type 1 receptor.
- Target
- Calcitonin gene-related peptide type 1 receptor
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
-
ritlecitinib
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in Pfizer's portfolio. Molecular target: TEC family kinase.
- Target
- TEC family kinase
- Mechanism
- Tyrosine-protein kinase JAK3 inhibitor
-
sasanlimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Pfizer's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 antagonist
-
sildenafil
Genito-urinary system and sex hormones (G04)Genito-urinary system and sex hormones (G04) compound in Pfizer's portfolio. Mechanism: Phosphodiesterase 5A inhibitor.
- Mechanism
- Phosphodiesterase 5A inhibitor
-
US regulatory status: approved. Molecular target: cGMP-specific 3',5'-cyclic phosphodiesterase.
- Target
- cGMP-specific 3',5'-cyclic phosphodiesterase
- Mechanism
- Phosphodiesterase 5A inhibitor
-
sirolimus
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
sunitinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Pfizer's portfolio. Molecular target: Macrophage colony-stimulating factor 1 receptor.
- Target
- Macrophage colony-stimulating factor 1 receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Macrophage colony-stimulating factor 1 receptor.
- Target
- Macrophage colony-stimulating factor 1 receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
talazoparib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Pfizer's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase 2 inhibitor
-
Development asset linked to Pfizer in public FDA and regional records. Mechanism: Estrogen receptor alpha modulator.
- Mechanism
- Estrogen receptor alpha modulator
-
temsirolimus
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Peptidyl-prolyl cis-trans isomerase FKBP1A.
- Target
- Peptidyl-prolyl cis-trans isomerase FKBP1A
- Mechanism
- FK506-binding protein 1A inhibitor
-
US regulatory status: approved. Molecular target: Beta-1 adrenergic receptor.
- Target
- Beta-1 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor antagonist
-
tofacitinib
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Mechanism: Janus Kinase (JAK) inhibitor.
- Mechanism
- Janus Kinase (JAK) inhibitor
-
US regulatory status: approved. Molecular target: Janus Kinase (JAK).
- Target
- Janus Kinase (JAK)
- Mechanism
- Janus Kinase (JAK) inhibitor
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
valdecoxib
Musculo-skeletal system (M01)US regulatory status: approved. Molecular target: Prostaglandin G/H synthase 2.
- Target
- Prostaglandin G/H synthase 2
- Mechanism
- Cyclooxygenase-2 inhibitor
-
Development asset linked to Pfizer in public FDA and regional records. Molecular target: Calcitonin-gene-related peptide receptor, CALCRL/RAMP1.
- Target
- Calcitonin-gene-related peptide receptor, CALCRL/RAMP1
- Mechanism
- Calcitonin-gene-related peptide receptor, CALCRL/RAMP1 antagonist
-
Development asset linked to Pfizer in public FDA and regional records. Mechanism: Dopamine D2 receptor antagonist.
- Mechanism
- Dopamine D2 receptor antagonist